You are here

Updated Label for NovoSeven Highlights Increased Risk of Arterial Thromboembolic Events

December 1, 2005 -- ROCKVILLE, MD -- Novo Nordisk and FDA notified healthcare professionals of revisions to the Warnings and Adverse Reactions sections of the prescribing information for NovoSeven, to provide updated safety information on thrombotic and thromboembolic adverse events, based on clinical studies in non-hemophilia patients and on post-marketing safety surveillance. A clinical study in elderly, non-hemophiliac, intracerebral hemorrhage patients indicated a potential increased risk of arterial thromboembolic adverse events with use of NovoSeven, including myocardial ischemia, myocardial infarction, cerebral ischemia and/or infarction.

Read the complete MedWatch 2005 Safety summary, including links to the "Dear Healthcare Professional" letter and revised prescribing information, at:

Source: The Food and Drug Administration

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs